MDxHealth SA Stock Euronext Bruxelles
Stocks
MDXH
BE0974461940
Biotechnology & Medical Research
| Market Cap | 24.3M 27.87M 22.51M 21.07M 39.51M 2.63B 39.75M 267M 103M 1.29B 105M 102M 4.49B | P/E 2026 * |
-0.84x | P/E 2027 * | -1.2x |
|---|---|---|---|---|---|
| Enterprise Value | 145M 166M 134M 126M 236M 15.69B 237M 1.59B 617M 7.72B 624M 611M 26.81B | EV / Sales 2026 * |
1.52x | EV / Sales 2027 * | 1.52x |
| Free-Float |
88.87% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MDxHealth SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2019-02-17 | |
Ron Kalfus
DFI | Director of Finance/CFO | 52 | 2019-07-21 |
Miriam Reyes
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Hilde Windels
BRD | Director/Board Member | 61 | 2017-10-31 |
Koen Hoffman
CHM | Chairman | 58 | 2017-12-31 |
| Director/Board Member | 64 | 2019-02-17 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.58% | - | - | 27.89M | |
| +1.44% | +1.71% | -10.98% | -6.19% | 43.13B | |
| +3.31% | +5.93% | +310.97% | +534.70% | 34.65B | |
| +2.84% | +2.14% | +9.34% | +41.02% | 30.03B | |
| -1.70% | -7.54% | +8.43% | -21.94% | 28B | |
| -1.90% | -1.56% | +10.24% | +21.21% | 24.45B | |
| -0.14% | +5.86% | - | - | 14.34B | |
| +0.68% | -1.53% | +48.76% | +104.27% | 13.14B | |
| -0.57% | -2.43% | +5.08% | +4.79% | 12.53B | |
| -0.26% | +1.15% | +98.13% | +80.47% | 12.25B | |
| Average | +0.37% | +0.73% | +60.00% | +94.79% | 23.61B | |
| Weighted average by Cap. | +0.77% | +1.27% | +65.47% | +110.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 95.34M 109M 88.3M 82.66M 155M 10.32B 156M 1.05B 406M 5.08B 410M 402M 17.63B | 107M 123M 99.37M 93.02M 174M 11.61B 176M 1.18B 457M 5.72B 462M 452M 19.84B |
| Net income | -27.8M -31.89M -25.75M -24.1M -45.21M -3.01B -45.48M -305M -118M -1.48B -120M -117M -5.14B | -17.91M -20.54M -16.59M -15.53M -29.12M -1.94B -29.3M -197M -76.26M -954M -77.1M -75.45M -3.31B |
| Net Debt | 121M 138M 112M 105M 196M 13.06B 197M 1.33B 514M 6.43B 519M 508M 22.31B | 139M 159M 128M 120M 225M 15B 227M 1.52B 590M 7.38B 597M 584M 25.63B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
